Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The bispecific blind spot: Uncovering real-world inequities in diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma therapy access

View Full Paper
Ask AI
Bookmark
Share

Authors

GHGene HoCRCleo A. RyalsAPAmy Pierre

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis reveals socioeconomic disparities in bispecific antibody access in lymphoma and myeloma patients, indicating the need for equitable treatment initiations.

Key Points

  • This research aimed to uncover inequities in the access to bispecific antibody therapy among patients with hematologic malignancies.
  • Retrospective cohort study using electronic health records from Flatiron Health Research Database.
  • Included patients with diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma on multiple treatment lines.
  • Assessed inequalities in treatment initiation according to demographics and social determinants of health.
  • 12% of patients received bispecific antibodies only, with 21% receiving CAR T-cell therapy.
  • Higher bispecific antibody initiation was found in patients from higher socioeconomic status neighborhoods.
  • Non-Latinx Black patients were more likely to receive bispecific antibodies compared to Non-Latinx White patients.

Cite This Study

Ho et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0c8https://doi.org/10.1182/blood-2025-8068
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evolving real-world uptake and patient characteristics of bispecific antibodies in Relapsed/Refractory multiple myeloma: Insights from a US community oncology network2025
  2. 2Impact of race and socioeconomics on access to T-cell engaging therapy in US patients with relapsed/refractory multiple myeloma (RRMM)2025
  3. 3Novel myeloma therapy utilization in digital health advocacy users: A large US cohort analysis of >1,500 patients.2026
  4. 4Real-world comparative outcomes of CAR-T cell therapy versus bispecific antibodies in patients with diffuse large B-cell lymphoma2025
  5. 5Treatment selection preferences and barriers in relapsed or refractory large B-cell lymphoma.2025